Motive:
In order to improve the treatment technique, a comprehensive follow-up program is needed to obtain all relevant patient, treatment and toxicity data from lung cancer patients.
Goal:
To set-up and maintain a database containing treatment results in terms of tumor control, side effects, complications and patient-reported quality of life.
A standard database of patients receiving photon treatment will be created. These data are then linked to dose-volume data of radiotherapy, with the aim to build prediction models for both tumor control and toxicity after radio (chemo) therapy that can later be used for selecting patients for proton treatment.
Patients with NSCLC or SCLC-LD or thymoma or lung metastases (treated with stereotactic radiotherapy)
Patients receiving radiotherapy dose > 40 Gy
Failure to comply with any of the inclusion criteria
Patients with Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer - Limited Disease (SCLC-LD) or thymoma or lungmetastases (treated with stereotactic radiotherapy), receiving radiotherapy dose \> 40 Gy.
Cohort
Prospective
Radiotherapy
RadiationAcute toxicity
esophagitis (Common Terminology Criteria for Adverse Events, version 4.0)
Late toxicity
esophagitis (Common Terminology Criteria for Adverse Events, version 4.0); pneumonitis (Common Terminology Criteria for Adverse Events, version 4.0)
Overall survival
Overall survival
Overall survival
Overall survival
Patient-rated symptoms and Quality-of-Life
Patient-rated symptoms and Quality-of-Life
Patient-rated symptoms and Quality-of-Life
Patient-rated symptoms and Quality-of-Life
Click on the lead sponsor to view all of their trials.
